Transcript immediate impact

2014 CQDM/CIHR COLLABORATIVE FUNDING PROGRAM IN
PERSONALIZED MEDICINE TO ACCELERATE DRUG DISCOVERY
Judith Caron,
Programs Director, CQDM
May 2014
THE ONLY PRE-COMPETITIVE PHARMA
CONSORTIUM IN CANADA
Our mission
To fund support breakthrough technologies
that will significantly enhance
biopharmaceutical R&D productivity and
accelerate the development of safer and
more efficacious drugs
To create a collaborative ground between
the academic and private sectors based on
trust, creativity and mutual benefit
A COLLABORATIVE APPROACH TO SHARE
THE R&D COSTS AND THE RESULTS
This model allows
• High financial leverage
(10- 20 fold)
• To derisk R&D
• To improve R&D productivity
Each pharma member has
a non-exclusive end-user
licence option for R&D
• Fully paid-up
• Worldwide
• Perpetual
OUR FUNDING PROGRAMS
Focus on technologies that accelerate drug discovery
Focus
Large scale
Multidisciplinary
Immediate impact on
drug discovery
$2M / project
Québec/Ontario
Large scale
Collaboration QC/ON
Immediate impact
$1M / project
Québec/Massasuchetts
Large scale
Collaboration QC/Mass
Late stage R&D
$2M / project
Explore
Highly innovative
Disruptive technologies
Early concept validation
$300 k / project
Québec/France
Large scale
Collaboration QC/Fr
Immediate impact
$1.4M / project
Pan Canadian
Large scale
Canadian network
Immediate impact
$1.5M / project
HIGHLIGHTS
Raised $65 M of public
and private funding
Established an international
mentorship program (over 80 mentors)
Completed 18 competitions
within 6 funding programs
450 projects reviewed
Built a strong R&D ecosystem including
pharmas, SEMs and academia
OUR PORTFOLIO
32 research projects for a total of $37,3M
46 research entities
• 25 academic institutions
• 21 private companies
Several different sectors of activity
Engineering – imaging – photonics – nanotechnologies –
instrumentations – biomarker development – discovery
platforms – drug delivery
A network of 400 researchers
A clear focus on
Scientific excellence and innovation
Strong impact on biopharmaceutical research
Translational research
Multidisciplinary approach
Public/private partnerships
SEVERAL THERAPEUTIC INDICATIONS
Across many sectors of activities
Genomics
System biology
Informatics
Chemistry
Engineering
Biomaterials
Imaging
Diagnostic
Physics
Medical devices
Pharmacology
Biochemistry
Cell Biology
Clinical sciences
Proteomics
Nanotechnology
Biophysics
Physiology
THE MENTORSHIP PROGRAM: A WIN/WIN COMBINATION
 Each project is assigned a mentor
from each pharma sponsor
 The mentors are international
experts from the global Pharma
organizations
 The mentors meet with the
investigators twice a year, on site,
and provide guidance on how to
deliver results with highest impact
 They can provide some additional
resources (clinical samples,
database, specific expertise)
A network of 80 mentors
 The mentors become the
champions of the funded projects
in their respective corporate
organizations
RIGHTS FOR CQDM PHARMA MEMBERS
CQDM
project
Background IP
Owned by
Researchers and
Research
Entities
Results
Deliverables
New IP
Know how
Data
Copyrights
No new IP
R&D use
Fully paid-up, perpetual, worldwide licence
option to use deliverables for R&D
Results – data – process - technology - platform
Service agreement with the PI (when relevant)
OUR ACHIEVEMENTS
32 outstanding research projects engaging $37.3M
•
•
•
•
10 projects completed with a success rate of 90%
80% of the technology already used by the pharma members
3 major investments by pharma members to use the results at the end of the project
Success stories of great value for biopharmaceutical research
• HTS discovery platform for VLP vaccine antigens
• Biomarkers for monitoring beta cells mass and function in diabetes patients
• Biosensors for GPCR signaling pathways
• Early diagnosis of pulmonary hypertension
• ERG for non invasive stratification of psychiatric disorders
• Flash walk mapping for GPRCs
• Synthetic lethality in oncology
• Several tangibles economic benefits for Quebec and Canada
•
•
•
•
•
Support of 256 jobs
Technology maturation for 12 SMEs
25 partnerships with industry
Creation of 5 starts-up
Additional $14.5 M from industry
CQDM/CIHR COLLABORATIVE FUNDING
PROGRAM IN PERSONALIZED MEDICINE TO
ACCELERATE DRUG DISCOVERY
SCOPE OF THE CQDM/CIHR PROGRAM
• This pan-Canadian program offer public and private partners the
opportunity to work together to develop novel technologies and tools
that address current and critical challenges faced by the pharmaceutical
industry in the area of personalized medicine.
• To develop cutting-edge next-generation technologies, computational
tools and devices with an immediate and strong impact on the
discovery/development of new drugs
 Not intended to fund the development of specific molecules
 Not intended to fund the discovery of biomarkers with ‘’omics’’
approaches
RESEARCH AGENDA
 Research projects focused on the invention and development of next-generation
of technologies, computational tools and devices in the following research
areas:
 cancer
 infection and immunity
 neurodegeneration affecting cognition

No technologies/tools/devices funded through other initiatives in personalized
medicine

Broad range of research fields/disciplines: biological and health sciences,
chemistry, engineering, nanotechnologies, computational sciences, medical
devices, imaging, biosensors, in silico and in vitro screening systems, and
improved disease-relevant animal models, etc.
 Well-defined near-term application with potential to significantly impact
biopharmaceutical R&D
ELIGIBILITY
•
Research performed in Canada
•
Academic sector: laboratories, affiliated research institutes, hospitals
•
Private sector: SMEs, biotechs, CROs
•
Public/private partnerships mandatory: minimum 1 academic researcher
and 1 industrial researcher working collaboratively
•
Address most important challenges of the biopharmaceutical industry
•
Highly innovative projects with strong and wide potential impact on the
pharmaceutical drug R&D process and the Canadian healthcare system
•
Multinational pharmaceutical companies not eligible to receive funds
FUNDING SPECIFICS
• Duration: Up to 30 months
• Funds available: $750K maximum
• Private matching funds: 25% of total project cost (in cash, in kind,
combination)
• Eligible costs: Salary of research personnel; Material and supplies; Travel
expenses; Intellectual property costs; Administrative costs (up to 15% for
the CQDM portion). CIHR’s policies and general guidelines, including those
specific to overhead costs, will apply to its contribution
• Non-eligible costs: Equipment or facilities; Salary of the principal
investigator and co-investigators
REVIEW AND DECISION PROCESS
CQDM/CIHR joint
committee
Full
applications
LOI
CQDM/CIHR joint
committee
Fit program +
matching funds
requirements
IMPACT
Fund in order of scientific merit
 3-step process: CQDM/CIHR joint committee to
decide before Scientific evaluation
Scientific evaluation
External review committee
IMPACT
CQDM/CIHR joint
committee
Board
Final selection
Research agreement
Projects start
16
EVALUATION CRITERIA OF THE FULL PROPOSALS
•
Scientific excellence and novelty
•
Potential of applications in drug research
o immediate impact on drug discovery or drug development
o capacity to address important unmet needs
•
Clear well-defined deliverables and milestones
•
Global competitiveness
•
Team expertise/experience
•
Quality of collaboration
•
Alignment with corporate objectives of the private partner(s)
IMPACT ON THE DRUG R&D PROCESS
• Identify most important challenges currently faced by the
pharmaceutical industry
• How will you project address them?
• How will the expected results and the deliverables of the project
impact the drug R&D process? Please specifically discuss the following
possible impacts (if applicable):




Opening new therapeutic approaches and research avenues
Bringing more effective medicines to the clinic and to the market
Increasing the efficacy of existing drugs
Reducing the R&D costs, time to market or the risks of
development
 Other impacts on the drug discovery and development process
POSITIONING/GLOBAL COMPETITIVENESS
• Not about the team or facilities
• It’s all about the technology, product, tool, device
• Identify:
 Current state of the art
 Competition:
o Direct and indirect
o Local and international
o Existing or in development
• Compare your technology, product, tool, device
• Bring out:
 Advantages
 Differentiating factors
 Originality and novelty aspects
MANAGEMENT OF FUNDED PROJECTS
• Projects are deliverables-based and milestones driven
• Research agreement included:
 Semi-annual milestones
 Deliverables
 Detailed budget
 Gantt chart: major steps, milestones, deliverables, budget
• Ensure success of project
MENTORSHIP PROGRAM: ONE OF A KIND
• Minimally one pharma mentor
 Opportunity for researchers to create strong links
and collaborate with pharma industry
 Two meetings/year (co-ordinated by CQDM)
 Informal interactions throughout year
• Mentors role?
 Ensure technology developed fully aligned with
industry needs
 Eager to aid with project success in mind (not to
evaluate)
 May provide additional resources (clinical samples,
database, specific expertise)
... mutual benefits for researchers and CQDM pharma members
TIMELINES CQDM/CIHR 2014 COMPETITION
Important dates
Program launch
March 18th, 2014
Deadline for submission of the letters of intent
June 27th, 2014
Announcement of the selected letters of intent
September 11th, 2014
Deadline to submit full proposals
November 27th, 2014
Final selection announcement
March 31st, 2015
Signature of a research agreement
Three months window
Funding release and beginning of the projects
July 1st, 2015
EXAMPLES OF DELIVERABLES
 Software for data analysis or data measurement
 Diagnostic tools
 Imaging tools
 Medical devices or instruments
 Prototypes
 Delivery systems
 Predictive algorithms
 Etc......
EXAMPLES OF PROJECTS
Cancer
Richard Kremer
Platform for the enrichment
of CTCs to follow disease
progression/treatment
outcome
Infection & Immunity
Michel Bergeron
Profiling the gut
microbiome to predict the
emergence of antibiotic
resistance
http://www.cqdm.org/en/projects-portfolio/
Neurodegeneration
affection cognition
Rick Hoge
Profiling patients with AD
using a new MRI
technique
CONTACT INFORMATION
Judith Caron
Director of Programs
CQDM
[email protected]
Olivier Jacob-Gravel
Program Delivery Coordinator
CIHR
[email protected]
More information:
http://www.cqdm.org
http://cqdm.org/en/programs-andcompetitions/cqdm-cihrcompetition.php
http://www.cihr-irsc.gc.ca/e/48082.html
Etienne Richer
Assistant Director
CIHR Institute of Genetics
[email protected]
Merci de votre attention!
Thank you for your participation!